Insilico Medicine Turns AI Drug Discovery Growth Into a First-Half Profit
Insilico Medicine has reported its first profitable half-year as a public company, giving one of China’s best-known AI drug-discovery firms a new commercial marker in a field often defined by long research timelines and costly clinical risk.